Results 121 to 130 of about 16,400 (171)

Composition of HBsAg is predictive of HBsAg loss during treatment in patients with HBeAg-positive chronic hepatitis B

Journal of Hepatology, 2021
During treatment of chronic HBV infections, loss or seroconversion of the HBV surface antigen (HBsAg) is considered a functional cure. HBsAg consists of the large (LHBs), middle (MHBs), and small surface protein (SHBs) and their relative proportions correlate strongly with disease stage.
Stephan Bohm, Wolfram H Gerlich, Dieter Glebe   +2 more
exaly   +3 more sources

Baseline Hepatitis B Surface Antigen (Hbsag) as Predictor of Sustained Hbsag Loss in Chronic Hepatitis B Patients Treated with Pegylated Interferon-α2A and Adefovir

Antiviral Therapy, 2013
Background In this study, we aimed to identify baseline predictors of response in chronic hepatitis B patients treated with a combination of pegylated interferon (PEG-IFN)-α2a and adefovir. Methods We treated 92 chronic hepatitis B ...
Takkenberg, R. Bart, Jansen, Louis, de Niet, Annikki, Zaaijer, Hans L., Weegink, Christine J., Terpstra, Valeska, Dijkgraaf, Marcel G. W., Molenkamp, Richard, Jansen, Peter L. M., Koot, Maarten, Rijckborst, Vincent, Janssen, Harry L. A., Beld, Marcel G. H. M., Reesink, Hendrik W.   +13 more
core   +5 more sources

LOSS OF HBsAg WITH INTERFERON THERAPY IN CHRONIC HEPATITIS B VIRUS INFECTION

Lancet, The, 1987
46 male chronic hepatitis B virus (HBV) carriers with active viral replication were randomised, with stratification for histology and sexual preference, to receive six months' lymphoblastoid interferon or no therapy. After nine to eighteen months' follow-up, HBeAg was no longer detectable and anti-HBe was present in 6 of the 23 treated patients.
Heather M Smith, A L Eddleston, J Brahm
exaly   +3 more sources

Comparative biomarkers for HBsAg loss with antiviral therapy shows dominant influence of quantitative HBsAg (qHBsAg)

Alimentary Pharmacology & Therapeutics, 2020
SummaryBackgroundBiomarkers such as quantitative HBsAg (qHBsAg), quantitative hepatitis B virus (HBV) core‐related antigen (qHBcrAg) and HBV RNA may be useful in predicting HBsAg loss in patients with chronic hepatitis B (CHB) undergoing antiviral therapy.Aim(s)Our study evaluated qHBsAg, HBV RNA and qHBcrAg as a posthoc analysis of a randomized ...
Seng Gee Lim, Wah Wah Phyo, Joanna Zhi Jie Ling, Gavin Cloherty, Emily K. Butler, Mary C. Kuhns, Anne L. McNamara, Vera Holzmayer, Jeffrey Gersch, Wei Lyn Yang, Jing Hieng Ngu, Jason Chang, Jessica Tan, Taufique Ahmed, Yock Young Dan, Yin Mei Lee, Guan Huei Lee, Poh Seng Tan, Daniel Q. Huang, Htet Toe Wai Khine, Chris Lee, Amy Tay, Edwin Chan   +22 more
openaire   +2 more sources

ALT flares during nucleotide analogue therapy are associated with HBsAg loss in genotype A HBeAg‐positive chronic hepatitis B [PDF]

Liver International, 2018
BACKGROUND: Alanine aminotransferase (ALT) flares during NA therapy are uncommon but occur. Evaluation of ALT flares during nucleos(t)ide analogue (NA) therapy is important as new immunomodulatory therapies for hepatitis B virus (HBV) are developed.
Darren Wong, Margaret Littlejohn, Kathy Jackson   +2 more
exaly   +2 more sources

Characterization of the structural modifications accompanying the loss of HBsAg particle immunogenicity

Vaccine, 2014
The aim of this work was to further understand the relationship between the immunogenicity and the structure of Hepatitis B surface antigen (HBsAg) particles used in Hepatitis B vaccines. To reach this aim, we compared by using a large range of techniques, the structure and properties of untreated particles with those of particles stored for 3 weeks at
Vanille J, Greiner, Catherine, Manin, Eric, Larquet, Nabila, Ikhelef, Frédéric, Gréco, Sophie, Naville, Pierre-Emmanuel, Milhiet, Frédéric, Ronzon, Andrey, Klymchenko, Yves, Mély   +9 more
openaire   +2 more sources

Loss of HBsAg and antiviral treatment: from basics to clinical significance

Hepatology International, 2014
Accurate prediction of the sustained virological response (SVR) to antiviral therapy against chronic hepatitis B (CHB) is still a crucial problem needing profound investigation. In recent years, quantification of hepatitis B surface antigen (HBsAg), a reliable predictor of SVR and an ideal endpoint of treatment, has attracted increasing attention ...
Yuecheng, Yu, Jinlin, Hou, Masao, Omata, Yue, Wang, Lanjuan, Li   +4 more
openaire   +2 more sources

Spontaneous loss of HBsAg in children with chronic hepatitis B virus infection

Hepatology, 1992
Spontaneous loss of HBsAg is infrequent in adult HBV carriers. Little is known about this serological change in children. In a prospective study of 420 hepatitis B virus-carrier children who were observed for 1 to 12 yr (mean = 4.3 yr), spontaneous loss of HBsAg occurred in 10 patients, with an average incidence of 0.6%/yr ...
HSU, HONG-YUAN, CHANG, MEI-HWEI, LEE, CHIN-YUN, CHEN, JUI-SAN, HSU, HEY-CHI, CHEN, DING-SHINN   +5 more
openaire   +2 more sources

Prediction of Treatment-Related HBsAg Loss in HBeAg-Negative Chronic Hepatitis B: A Clue from Serum HBsAg Levels

Antiviral Therapy, 2007
Background Quantification of HBsAg in serum may be of clinical importance in predicting HBsAg seroconversion and complete response to treatment. Methods Serum HBsAg was quantified by ADVIA Centaur® in 63 patients with HBeAg-negative ...
Emanuel K, Manesis, Emilia S, Hadziyannis, Olga P, Angelopoulou, Stephanos J, Hadziyannis   +3 more
openaire   +2 more sources

Off‐therapy precipitous HBsAg decline predicts HBsAg loss after finite entecavir therapy in HBeAg‐negative patients

Journal of Viral Hepatitis, 2019
AbstractCessation of nucleos(t)ide analogue (Nuc) therapy in HBeAg‐negative patients may increase HBsAg loss rate in patients with sustained remission (SR) and non‐retreated clinical relapsers (CR). To investigate and compare the HBsAg kinetics from end of treatment (EOT) to HBsAg loss in these patients, serial serum samples after EOT from 36 SR and 12
Wen‐Juei Jeng, Ming‐Ling Chang, Yun‐Fan Liaw   +2 more
openaire   +2 more sources